National Institute on Aging; Amended Notice of Meeting, 52889 [2019-21490]
Download as PDF
<![CDATA[
Federal Register / Vol. 84, No. 192 / Thursday, October 3, 2019 / Notices
(Catalogue of Federal Domestic Assistance
Program Nos. 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Clinical Aging
Review Committee, September 26, 2019,
12:00 p.m. to September 27, 2019, 12:00
p.m., Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814 which
was published in the Federal Register
on July 31, 2019, 84 FR 37328.
The meeting notice is amended to
change the time of the meeting from
12:00 p.m.–12:00 p.m. to 9:00 a.m.–1:00
p.m. The meeting is closed to the
public.
Dated: September 27, 2019.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–21490 Filed 10–2–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Compositions, Devices
and Processes for Production and
Delivery of Cell Grafts of Manufactured
Retinal Pigment Epithelium Cell(s)
Alone, or in Combination With
Photoreceptor Cells, and on a
Biodegradable Support Scaffold
Transplanted Subretinally for IntraOcular Ophthalmic Treatment of
Conditions of Degeneration,
Dysfunction or Terminal Injury of
Retinal Pigment Epithelium and/or
Photoreceptors in Humans
ACTION:
National Institutes of Health,
Notice.
The National Eye Institute, an
institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patents and Patent Applications listed
in the SUPPLEMENTARY INFORMATION
section of this notice to Opsis
Therapeutics, LLC, (‘‘Opsis’’) located in
Madison Wisconsin and its affiliate,
FUJIFILM Cellular Dynamics, Inc.
DATES: Only written comments and/or
complete applications for a license
which are received by the National
Cancer Institute’s Technology Transfer
Center on or before October 18, 2019
will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Edward Fenn., Senior
Technology Transfer Manager, NCI
Technology Transfer Center, 9609
Medical Center Drive, RM 1E530 MSC
9702, Bethesda, MD 20892–9702 (for
business mail), Rockville, MD 20850–
9702; Telephone: (240) 276–5530;
Facsimile: (240) 276–5504 Email:
Tedd.Fenn@nih.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Outreach and Education to Health Care
Providers on Substance Use (1159).
Date: October 22, 2019.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Lyle Furr, Scientific
Review Officer, Office of Extramural Affairs,
National Institute on Drug Abuse, NIH,
DHHS, Room 220, MSC 8401, 6101 Executive
Boulevard, Bethesda, MD 20892–8401, (301)
435–1439, lf33c@nih.gov.
Jkt 250001
BILLING CODE 4140–01–P
HHS.
National Institute on Drug Abuse;
Notice of Closed Meeting
17:22 Oct 02, 2019
[FR Doc. 2019–21491 Filed 10–2–19; 8:45 am]
AGENCY:
National Institutes of Health
VerDate Sep<11>2014
Dated: September 27, 2019.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
PO 00000
Frm 00022
Fmt 4703
Sfmt 4703
52889
Intellectual Property
• PCT Patent App. No. PCT/US2015/
039932, filed 07/10/15 (NIH Ref. E–192–
2014–1–PCT–01); United States Patent
App. No. 15/325,584, filed 01/11/17
(NIH Ref. E–192–2014–1–US–02);
Australia Patent App. No. 2015287692,
filed 07/10/15 (NIH Ref. E–192–2014–1–
AU–03); Canada Patent App. No.
2954762, filed 07/10/15 (NIH Ref. E–
192–2014–1–CA–04); PEC Patent App.
No. 15741462.4, filed 07/10/15 (NIH
Ref. E–192–2014–1–EP–05); India Patent
App. No. 01717003244, filed 01/30/17
(NIH Ref. E–192–2014–1–IN–06); Japan
Patent App. No. 2017–501212 Filed 01/
10/17 (NIH Ref. E–192–2014–1–JP–07);
each entitled ‘‘Surgical Tool and
Method for Ocular Tissue
Transplantation’’;
• United States Patent App. No. 62/
215,579, filed 09/08/15 (NIH Ref. E–
212–2015–0–US–01); PCT Patent App.
No. PCT/US2016/050543, filed 09/07/16
(NIH Ref. E–212–2015–0–PCT–02);
Australia Patent App. No. 2016321170,
filed 03/21/18 (NIH Ref. E–212–2015–0–
AU–03); Canada Patent App. No.
2997952, filed 09/07/16 (NIH Ref. E–
212–2015–0–CA–04); EPC Patent App.
No. 16766444.0, filed 09/07/16 (NIH
Ref. E–212–2015–0–EP–05); Japan
Patent App. No. 2018–512373, filed 03/
07/18 (NIH Ref. E–212–2015–0–JP–06);
United States Patent App. No. 15/
758,314, filed 03/07/18 (NIH Ref. E–
212–2015–0–US–07); China patent
application No. 201680060872.4, filed
04/18/2018 (NIH Ref. pending); Korea
patent application No. 1020187009942,
file 04/06/2018 (NIH Ref. pending); each
entitled ‘‘Method for Reproducible
Differentiation of Clinical-Grade Retinal
Pigment Epithelium Cells’’;
• United States Provisional Patent
App. No. 62/419,804, filed 11/09/16
(NIH Ref. E–293–2016–0–US–01); PCT
Patent App. No. PCT/US2017/060672,
filed 11/08/17 (NIH Ref. E–293–2016–0–
PCT–02); Australia Patent App. No.
2017359336, filed 11/08/17 (NIH Ref. E–
293–2016–0–AU–04); Canada Patent
App. No. 3043174, filed 11/08/17 (NIH
Ref. E–293–2016–0–CA–05); EPC Patent
App. No. 17801272.0, filed 11/08/17
(NIH Ref. E–293–2016–0–EP–06); Japan
Patent App. No. pending (NIH Ref. E–
293–2016–0–JP–07); United States
Patent App. No. 16/348,855, filed 05/09/
2019 (NIH Ref. E–293–2016–0–US–03);
each entitled ‘‘A Surgical Clamp to Gate
Large Scleral Surgery Port and Suture
Alignment Tool’’;
• United States Patent App. No. 62/
453,148, filed 02/01/17 (NIH Ref. E–
094–2016–0–US–01); PCT Patent App.
No. PCT/US2018/016101, Filed 01/31/
18 (NIH Ref. E–094–2016–0–PCT–02)
E:\FR\FM\03OCN1.SGM
03OCN1
]]>Agencies
[Federal Register Volume 84, Number 192 (Thursday, October 3, 2019)]
[Notices]
[Page 52889]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-21490]
[[Page 52889]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Amended Notice of Meeting
Notice is hereby given of a change in the meeting of the Clinical
Aging Review Committee, September 26, 2019, 12:00 p.m. to September 27,
2019, 12:00 p.m., Hyatt Regency Bethesda, One Bethesda Metro Center,
7400 Wisconsin Avenue, Bethesda, MD 20814 which was published in the
Federal Register on July 31, 2019, 84 FR 37328.
The meeting notice is amended to change the time of the meeting
from 12:00 p.m.-12:00 p.m. to 9:00 a.m.-1:00 p.m. The meeting is closed
to the public.
Dated: September 27, 2019.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-21490 Filed 10-2-19; 8:45 am]
BILLING CODE 4140-01-P
